CN112390887B - 抗体、产生所述抗体的杂交瘤、及其用途 - Google Patents

抗体、产生所述抗体的杂交瘤、及其用途 Download PDF

Info

Publication number
CN112390887B
CN112390887B CN202011258954.4A CN202011258954A CN112390887B CN 112390887 B CN112390887 B CN 112390887B CN 202011258954 A CN202011258954 A CN 202011258954A CN 112390887 B CN112390887 B CN 112390887B
Authority
CN
China
Prior art keywords
antigen
antibody
amino acid
seq
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011258954.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112390887A (zh
Inventor
游丞德
赖建勋
陈怡如
王正琪
蔡易芊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBI Pharma Inc
Original Assignee
OBI Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBI Pharma Inc filed Critical OBI Pharma Inc
Priority to CN202011258954.4A priority Critical patent/CN112390887B/zh
Publication of CN112390887A publication Critical patent/CN112390887A/zh
Application granted granted Critical
Publication of CN112390887B publication Critical patent/CN112390887B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CN202011258954.4A 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途 Active CN112390887B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011258954.4A CN112390887B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US61/977,824 2014-04-10
US201462057381P 2014-09-30 2014-09-30
US62/057,381 2014-09-30
CN202011258954.4A CN112390887B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途
CN201580011286.6A CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途
PCT/US2015/025305 WO2015157629A2 (en) 2014-04-10 2015-04-10 Antibodies, pharmaceutical compositions and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580011286.6A Division CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Publications (2)

Publication Number Publication Date
CN112390887A CN112390887A (zh) 2021-02-23
CN112390887B true CN112390887B (zh) 2023-09-26

Family

ID=54288553

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580011286.6A Active CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途
CN202011258954.4A Active CN112390887B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580011286.6A Active CN106456727B (zh) 2014-04-10 2015-04-10 抗体、产生所述抗体的杂交瘤、及其用途

Country Status (17)

Country Link
US (2) US9902779B2 (OSRAM)
EP (2) EP3662928A1 (OSRAM)
JP (1) JP2017512759A (OSRAM)
KR (1) KR101966408B1 (OSRAM)
CN (2) CN106456727B (OSRAM)
AU (2) AU2015243246B2 (OSRAM)
BR (1) BR112016020009A2 (OSRAM)
CA (2) CA3104268A1 (OSRAM)
CL (1) CL2016002569A1 (OSRAM)
ES (1) ES2772817T3 (OSRAM)
IL (2) IL246837B (OSRAM)
PH (1) PH12016501976A1 (OSRAM)
RU (1) RU2016138744A (OSRAM)
SG (1) SG11201607258SA (OSRAM)
TW (3) TWI697503B (OSRAM)
WO (1) WO2015157629A2 (OSRAM)
ZA (1) ZA201605175B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ714555A (en) 2013-09-17 2020-03-27 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
TWI681972B (zh) 2014-03-19 2020-01-11 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途
TWI697503B (zh) 2014-04-10 2020-07-01 台灣浩鼎生技股份有限公司 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途
AR105910A1 (es) 2015-09-04 2017-11-22 Obi Pharma Inc Matrices de glicano y método de uso
US10501532B2 (en) * 2015-10-07 2019-12-10 Obi Pharma, Inc. Carbohydrate antibodies, pharmaceutical compositions and uses thereof
EP3436482A4 (en) 2016-03-29 2020-03-11 OBI Pharma, Inc. ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CA3021548A1 (en) 2016-04-22 2017-10-26 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via globo series antigens
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CN110290800A (zh) * 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
JP7792191B2 (ja) * 2017-05-24 2025-12-25 ディベロップメント センター フォー バイオテクノロジー グロボｈに対するヒト化抗体および癌治療におけるその使用
JP7386800B2 (ja) * 2018-03-14 2023-11-27 メモリアル スローン－ケタリング キャンサー センター 抗ポリシアル酸抗体およびその使用
JP2021525756A (ja) * 2018-06-01 2021-09-27 オービーアイ ファーマ，インコーポレイテッド 抗グロボｈ又は抗ｓｓｅａ−４抗体を、抗ネガティブ免疫チェックポイント抗体と共に使用することによる組合せ療法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CA3136104A1 (en) * 2019-03-28 2020-10-01 Obi Pharma, Inc. Companion diagnostic assay for globo-h related cancer therapy
AU2022219922A1 (en) * 2021-02-09 2023-06-22 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535282A (zh) * 2001-04-06 2004-10-06 神经节苷脂相关的重组抗体及其在肿瘤的诊断和治疗中的应用
CN1997670A (zh) * 2004-07-01 2007-07-11 诺和诺德公司 人类抗－kir抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用
CN101589062A (zh) * 2006-09-20 2009-11-25 安姆根有限公司 与胰高血糖素受体抗体相关的组合物和方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
CN1423700A (zh) 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
EP1505075B1 (en) * 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
AT413486B (de) 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
PL2857418T3 (pl) 2004-02-06 2017-10-31 Univ Massachusetts Przeciwciała przeciw toksynom Clostridium difficile i ich zastosowania
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
JP4884395B2 (ja) * 2004-12-21 2012-02-29 アストラゼネカ エービー アンジオポエチン−２に対する抗体およびそれらの使用
DK1866339T3 (da) * 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
WO2010008736A2 (en) 2008-06-16 2010-01-21 Academia Sinica Cancer diagnosis based on levels of antibodies against globo h and its fragments
JP2011524375A (ja) 2008-06-16 2011-09-01 アカデミア シニカ ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
TWI583393B (zh) * 2009-06-16 2017-05-21 中央研究院 免疫原性組合物、包含其之疫苗與治療劑及其用途
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
CN105968206B (zh) 2010-04-09 2020-01-17 Aveo制药公司 抗erbb3抗体
CN103459600B (zh) * 2010-07-01 2016-10-19 帝斯曼知识产权资产管理有限公司 用于生产感兴趣的化合物的方法
SG10201506405YA (en) * 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
TW201307388A (zh) * 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
EP2497782A1 (en) 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
NZ628804A (en) 2012-02-24 2017-08-25 Abbvie Stemcentrx Llc Dll3 modulators and methods of use
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
TWI681972B (zh) * 2014-03-19 2020-01-11 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 抗免疫原性醣肽之抗體，包含彼等之組合物及其用途
TWI697503B (zh) 2014-04-10 2020-07-01 台灣浩鼎生技股份有限公司 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1535282A (zh) * 2001-04-06 2004-10-06 神经节苷脂相关的重组抗体及其在肿瘤的诊断和治疗中的应用
CN1997670A (zh) * 2004-07-01 2007-07-11 诺和诺德公司 人类抗－kir抗体
CN101115773A (zh) * 2005-02-07 2008-01-30 格黎卡特生物技术股份公司 结合egfr的抗原结合分子，编码它的载体，及其应用
CN101589062A (zh) * 2006-09-20 2009-11-25 安姆根有限公司 与胰高血糖素受体抗体相关的组合物和方法

Also Published As

Publication number Publication date
TWI609886B (zh) 2018-01-01
IL276695B (en) 2021-09-30
CA3104268A1 (en) 2015-10-15
AU2015243246A1 (en) 2016-09-08
IL246837A0 (en) 2016-08-31
TW201738276A (zh) 2017-11-01
EP3129048B1 (en) 2020-01-15
CN112390887A (zh) 2021-02-23
RU2016138744A3 (OSRAM) 2018-05-11
CA2941029A1 (en) 2015-10-15
AU2018253589B2 (en) 2020-04-16
WO2015157629A3 (en) 2015-12-03
ZA201605175B (en) 2017-09-27
TWI697503B (zh) 2020-07-01
TW201738277A (zh) 2017-11-01
SG11201607258SA (en) 2016-10-28
US20170029526A1 (en) 2017-02-02
BR112016020009A2 (pt) 2017-10-17
IL246837B (en) 2020-08-31
CL2016002569A1 (es) 2017-09-08
CN106456727B (zh) 2020-11-27
KR101966408B1 (ko) 2019-04-05
TWI695013B (zh) 2020-06-01
EP3662928A1 (en) 2020-06-10
PH12016501976A1 (en) 2016-12-19
WO2015157629A2 (en) 2015-10-15
RU2016138744A (ru) 2018-05-11
EP3129048A4 (en) 2017-10-25
EP3129048A2 (en) 2017-02-15
US20180134799A1 (en) 2018-05-17
CA2941029C (en) 2021-02-16
CN106456727A (zh) 2017-02-22
US9902779B2 (en) 2018-02-27
IL276695A (en) 2020-09-30
AU2015243246B2 (en) 2018-09-06
ES2772817T3 (es) 2020-07-08
TW201546092A (zh) 2015-12-16
US10815307B2 (en) 2020-10-27
KR20160137984A (ko) 2016-12-02
AU2018253589A1 (en) 2018-11-22
JP2017512759A (ja) 2017-05-25

Similar Documents

Publication Publication Date Title
CN112390887B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
CN103917559B (zh) 艰难梭菌抗体
TWI811604B (zh) 抗體、醫藥組成物及其用途
AU2016335842A1 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
CN114761042A (zh) Il-38特异性抗体
HK1232767B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
HK40037463A (en) Antibodies, hybridoma producing such antibodies and uses thereof
HK40037463B (zh) 抗体、产生所述抗体的杂交瘤、及其用途
HK1232767A1 (en) Antibodies, hybridoma producing such antibodies and uses thereof
TW202302635A (zh) Ｉｌ－３８專一性抗體
WO2025038794A1 (en) Antibodies targeting serum amyloid a (saa) and uses thereof
CN117480188A (zh) 新颖糖类抗体、医药组成物及其用途
HK1199886B (en) Clostridium difficile antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40037463

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant